With reference to Regulation 30 & Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, Brooks Laboratories has informed that the Board of Directors at its meeting held today has, approved the Unaudited Standalone and Consolidated Financial Results of the Company for the 1st quarter ended 30 June, 2022. The Audit Committee reviewed the Unaudited Standalone and Consolidated Financial Results at its meeting held earlier today which have been subject to a limited review by the Statutory Auditors. The company has attached a copy of the approved Unaudited Standalone and Consolidated Financial Results for the quarter ended 30.06.2022 along with the Limited Review Report of the Auditors.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1653.80 |
| Dr. Reddys Lab | 1215.95 |
| Cipla | 1228.20 |
| Zydus Lifesciences | 927.75 |
| Lupin | 2307.30 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: